Patents by Inventor Shahrooz Rabizadeh

Shahrooz Rabizadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160026752
    Abstract: Omics patient data are analyzed using sequences or diff objects of tumor and matched normal tissue to identify patient and disease specific mutations, using transcriptomic data to identify expression levels of the mutated genes, and pathway analysis based on the so obtained omic data to identify specific pathway characteristics for the diseased tissue. Most notably, many different tumors have shared pathway characteristics, and identification of a pathway characteristic of a tumor may thus indicate effective treatment options ordinarily not considered when tumor analysis is based on anatomical tumor type only.
    Type: Application
    Filed: June 1, 2015
    Publication date: January 28, 2016
    Inventors: Shahrooz Rabizadeh, John Zachary Sanborn, Charles Joseph Vaske, Stephen Charles Benz, Patrick Soon-Shiong
  • Patent number: 9206443
    Abstract: An improved process for alcohol production includes microbial fermentation using a genetically modified microorganism to produce substantial quantities of aldehydes that are stripped from the fermentation medium and condensed. So produced aldehydes are converted in an ex vivo process to corresponding alcohols.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: December 8, 2015
    Assignee: Easel Biotechnologies, LLC
    Inventors: Wendy M. Higashide, Kwang Myung Cho, Shahrooz Rabizadeh
  • Publication number: 20150297572
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 22, 2015
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • Patent number: 9107863
    Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: August 18, 2015
    Assignee: The Buck Institute For Age Reasearch
    Inventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
  • Publication number: 20150088432
    Abstract: Contemplated systems and methods employ chimeric reference sequences that include a plurality of viral genome sequences to identify/quantify integration and co-amplification events. Most typically, the viral genome sequences are organized in the chimeric reference sequences as single chromosomes and the chimeric reference sequences are in BAM format.
    Type: Application
    Filed: September 26, 2014
    Publication date: March 26, 2015
    Inventors: John Zachary Sanborn, Charles Joseph Vaske, Stephen Charles Benz, Shahrooz Rabizadeh, Nicole Hensley, Patrick Soon-Shiong
  • Publication number: 20150006445
    Abstract: The present inventive subject matter provides apparatus, systems, and methods in which a diagnostic test is identified, where the diagnostic test is for determining whether a particular treatment is effective for a particular patient based on one or more characteristics of a patient's cells. When a treatment is developed with the potential to treat one or more diseases, the drug can have different effects on different cell lines related to the diseases. A machine learning system is programmed to infer a measurable cell characteristic, out of many different measurable cell characteristics, that has a desirable correlation with the sensitivity data of different cell lines to a treatment. The machine learning system is programmed to then determine, based on the correlation, a threshold level of the cell characteristic the patient should exhibit in order to recommend administering the treatment.
    Type: Application
    Filed: June 30, 2014
    Publication date: January 1, 2015
    Inventors: Stephen Charles Benz, Shahrooz Rabizadeh, Christopher Szeto, Paul Weingarten, Chunlin Tao
  • Patent number: 8895031
    Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: November 25, 2014
    Assignee: The Buck Institute for Age Research
    Inventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
  • Publication number: 20140322774
    Abstract: Microorganisms and methods of producing n-butyraldehyde with enhanced yields are presented in which a microorganism is engineered to enhance the conversion of a carbon source into n-butyraldehyde. The n-butyraldehyde is recovered by way of a gas stripping process that occurs during the conversion process, providing significantly greater product yield than post-fermentation recovery of n-butyraldehyde alone.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 30, 2014
    Inventors: Kwang Myung Cho, Wendy Higashide, Chrissie Lee, Shahrooz Rabizadeh
  • Publication number: 20140100228
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Application
    Filed: December 11, 2013
    Publication date: April 10, 2014
    Applicant: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure LeNy, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Patent number: 8633198
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: January 21, 2014
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20140011231
    Abstract: An improved process for alcohol production includes microbial fermentation using a genetically modified microorganism to produce substantial quantities of aldehydes that are stripped from the fermentation medium and condensed. So produced aldehydes are converted in an ex vivo process to corresponding alcohols.
    Type: Application
    Filed: March 14, 2012
    Publication date: January 9, 2014
    Applicant: Easel Biotechnologies, LLC
    Inventors: Wendy M. Higashide, Kwang Myung Cho, Shahrooz Rabizadeh
  • Publication number: 20120040457
    Abstract: This invention provides a novel screening system for identifying p53 mimetics/agonists. Also provided are small organic molecules that act as effective p53 mimetics/agonists.
    Type: Application
    Filed: June 24, 2011
    Publication date: February 16, 2012
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Dale E. Bredesen
  • Patent number: 7994184
    Abstract: This invention provides a novel screening system for identifying p53 mimetics/agonists. Also provided are small organic molecules that act as effective p53 mimetics/agonists.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: August 9, 2011
    Assignee: Buck Institute
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Dale E. Bredesen
  • Publication number: 20110104715
    Abstract: In accordance with the present invention, it has been discovered that the ?-amyloid precursor protein (APP), and two APP-like proteins (APLP1 and APLP2) are proteolytically cleaved by caspases in the C terminus to generate an approximately 31 amino acid peptide. It has been further discovered that the resultant C-terminal peptide is a potent inducer of apoptosis. Both caspase-cleaved APP and activated caspase-9 is present in brains of Alzheimer's disease patients but not in control brains. These findings indicate that caspase cleavage of APP and APP-like proteins leads to the generation of apoptotic peptides, which may contribute to the neuronal death associated with Alzheimer's disease. Accordingly, there are provided compositions and methods for modulating apoptosis.
    Type: Application
    Filed: August 31, 2009
    Publication date: May 5, 2011
    Inventors: Dale E. Bredesen, Shahrooz Rabizadeh
  • Publication number: 20100278874
    Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
    Type: Application
    Filed: April 29, 2010
    Publication date: November 4, 2010
    Inventors: Kayvan R. NIAZI, Shahrooz RABIZADEH, Dale E. BREDESEN
  • Publication number: 20070269457
    Abstract: A vaccine is described which provides protection against a broad spectrum of viral strains, including but not limited to influenza A strains such as H1N1, H3N2, and H5N1. Embodiments of the present invention offer a number of advantages over conventional vaccine, in that they are cheaper to synthesize, more stable, easily scalable, and amenable to further genetic manipulation. Most importantly, certain embodiments of the present invention contemplate features, including but not limited to endosomal targeting, which result in a more robust immune response.
    Type: Application
    Filed: May 16, 2006
    Publication date: November 22, 2007
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Dale Bredesen
  • Publication number: 20070224207
    Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
    Type: Application
    Filed: March 27, 2006
    Publication date: September 27, 2007
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Dale Bredesen
  • Publication number: 20060094738
    Abstract: This invention provides a novel screening system for identifying p53 mimetics/agonists. Also provided are small organic molecules that act as effective p53 mimetics/agonists.
    Type: Application
    Filed: August 12, 2005
    Publication date: May 4, 2006
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Dale Bredesen
  • Patent number: 6235872
    Abstract: The present invention provides substantially pure proapoptotic dependence peptides. The peptides consist substantially of the sequence of an active dependence domain selected from the group of dependence polypeptides consisting of p75NTR, androgen receptor, DCC, huntingtin polypeptide, Machado-Joseph disease gene product, SCA1, SCA2, SCA6 and atrophin-1 polypeptide. Substantially pure proapoptotic dependence peptides include SATLDALLAALRRI (SEQ ID NO:3), Q14 (SEQ ID NO:7), SATLDALLAALGGI (SEQ ID NO:4), SATLDALLAALRGI (SEQ ID NO:5), SATLQALLAALRRI (SEQ ID NO:6), tat-GG-SATLDALLAALRRI (SEQ ID NO:37) and tat-GG-Q14 (SEQ ID NO:36).
    Type: Grant
    Filed: March 12, 1998
    Date of Patent: May 22, 2001
    Assignee: The Burnham Institute
    Inventors: Dale E. Bredesen, Shahrooz Rabizadeh